> Is Colox® Reliable?
The performances of the test was validated in a multicenter clinical case-control study conducted in Switzerland, including 782 individuals. It detected 78% of patients with colon cancer and 52% of patients with adenomatous polyps. The test sensitivity for early stage detection is 61%. The specificity of the test is 92.2%, it means that less than 1 out of 10 people without any colorectal lesion tested positive.
Currently, 400 doctors have already prescribed Colox to more than 3,200 patients.
> What are the benefits of Colox® ?
Colox® is the most convenient screening test on the market that enables early diagnosis of colorectal cancer. It just needs a blood test compared to other more invasive and inconvenient tests, which require you to prepare your bowels or handle your stools. Moreover, it doesn’t require a hospital stay. Reliable clinical studies have proved the performance of the test for the effective detection of colorectal cancers. Moreover, Colox® has good performances for the detection of adenomatous polyps bigger than 1cm.
> Why a blood test ?
In Switzerland, only 10% of the target population agrees to perform a colonoscopy and 20% perform blood tests in the stool. This means that 70% of the population is not tested. A blood test has the potential to increase screening participation in the eligible population that is not currently screened. This test is therefore recommended for women and men who prefer the convenience of a blood test or who prefer the simplicity of a blood test to the invasive procedure of a screening colonoscopy.
